RxDoctor Payments DataLook up a doctor →

Sara Eapen, MD

Pediatrics · Richmond Hts, OHNPI 1962507301

Payments from drug & device makers

$12,790in general payments, 2019–2025

Across 783 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$979
  • Novo Nordisk$873
  • GSK$829
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$12,790100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,790 in reported general payments places this provider in the 95th percentile of 2,041 pediatrics providers in Ohio.

See all pediatrics providers in Ohio

Medicare billing

Part B allowed, 2024
$90,274
Medicare patients
182
Services billed
1,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$128,613
MounjaroTirzepatide82$101,827
RybelsusSemaglutide65$94,352
FarxigaDapagliflozin Propanediol75$80,112
TrulicityDulaglutide45$57,092
OzempicSemaglutide33$45,203
EliquisApixaban45$40,429
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$39,552
XareltoRivaroxaban13$21,802
ProliaDenosumab11$19,008
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$14,619
CreonLipase/Protease/Amylase12$14,289
LinzessLinaclotide20$13,777
KerendiaFinerenone14$10,405
Atorvastatin Calcium708$6,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,081$158,919127 claims
Novo NordiskRybelsus, Ozempic$873$139,55598 claims
Boehringer IngelheimJardiance$113$128,613118 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,185$99,227106 claims
GSKTrelegy Ellipta, Breo Ellipta$829$44,40364 claims
PfizerEliquis$979$40,42945 claims
AbbVieCreon, Linzess$2,010$28,06632 claims
Johnson & JohnsonXarelto$58$21,80213 claims
AmgenProlia$378$19,00811 claims
BayerKerendia$512$10,40514 claims
Astellas Pharma US IncMyrbetriq$452$6,53713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,041 pediatrics providers in Ohio.

Other pediatrics in Richmond Hts

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →